Literature DB >> 30536304

MiR-155 affects osteosarcoma cell proliferation and invasion through regulating NF-κB signaling pathway.

S Lu1, Q-S Liao, L Tang.   

Abstract

OBJECTIVE: Osteosarcoma can form tumor osteoid tissue and bone tissue directly or indirectly through cartilage stage. It mainly occurs in children and adolescents with high mortality. MicroRNA (miRNA) possesses tissue sensitivity as tumor biomarker and plays a promoting or inhibitory role in tumor pathogenesis as oncogene or tumor suppressor gene. It was found that miR-155 was abnormally expressed in tumor and could be treated as a biomarker for cancer progression. However, miR-155 expression in osteosarcoma and related mechanism still remains unclear. This study aimed to explore the role of miR-155 in osteosarcoma occurrence and development.
MATERIALS AND METHODS: Osteosarcoma cell line MG-63 was cultured in vitro and transfected by miR-155 mimics or inhibitor. MiR-155 expression was examined by Real-time PCR (RT-PCR). Cell proliferation was evaluated by MTT assay. Caspase 3 activity was determined by caspase 3 activity detection kit. Cell invasion was measured by transwell assay. B-cell lymphoma-2 (Bcl-2) and nuclear factor κB (NF-κB) protein expressions were assessed by Western blot.
RESULTS: MiR-155 mimics significantly up-regulated miR-155 expression, promoted MG-63 cell proliferation and invasion, inhibited caspase 3 activity, and up-regulated expressions of NF-κB and Bcl-2 compared with control group (p < 0.05). However, miR-155 inhibitor significantly inhibited MG-63 cell proliferation and invasion, enhanced caspase 3 activity, and reduced expressions of NF-κB and Bcl-2 compared with control group (p < 0.05).
CONCLUSIONS: MiR-155 affected osteosarcoma cell proliferation and apoptosis through regulating NF-κB signaling pathway, indicating it might be a new biomarker for osteosarcoma diagnosis and treatment.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30536304     DOI: 10.26355/eurrev_201811_16380

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  9 in total

1.  miR-155, miR-191, and miR-494 as diagnostic biomarkers for oral squamous cell carcinoma and the effects of Avastin on these biomarkers.

Authors:  Naghmeh Emami; Abdolreza Mohamadnia; Masoumeh Mirzaei; Mohammad Bayat; Farnoush Mohammadi; Naghmeh Bahrami
Journal:  J Korean Assoc Oral Maxillofac Surg       Date:  2020-10-31

Review 2.  miR-155-3p: processing by-product or rising star in immunity and cancer?

Authors:  Owen Dawson; Anna Maria Piccinini
Journal:  Open Biol       Date:  2022-05-25       Impact factor: 7.124

Review 3.  Exosomal MiRNAs in Osteosarcoma: Biogenesis and Biological Functions.

Authors:  Jinxin Tang; Jieyu He; Chengyao Feng; Chao Tu
Journal:  Front Pharmacol       Date:  2022-05-03       Impact factor: 5.988

Review 4.  MicroRNAs: The Link between the Metabolic Syndrome and Oncogenesis.

Authors:  Adriana Fodor; Andrada Luciana Lazar; Cristina Buchman; Brandusa Tiperciuc; Olga Hilda Orasan; Angela Cozma
Journal:  Int J Mol Sci       Date:  2021-06-13       Impact factor: 5.923

5.  Triptolide Inhibits Preformed Fibril-Induced Microglial Activation by Targeting the MicroRNA155-5p/SHIP1 Pathway.

Authors:  Yang Feng; Chuyun Zheng; Yajun Zhang; Changyang Xing; Wenbin Cai; Ruru Li; Jianzong Chen; Yunyou Duan
Journal:  Oxid Med Cell Longev       Date:  2019-04-28       Impact factor: 6.543

6.  Development of a prognostic gene signature based on an immunogenomic infiltration analysis of osteosarcoma.

Authors:  Yiyang Yu; Hongliang Zhang; Tingting Ren; Yi Huang; Xin Liang; Wei Wang; Jianfang Niu; Yu Han; Wei Guo
Journal:  J Cell Mol Med       Date:  2020-08-21       Impact factor: 5.310

7.  Research Progress of Exosome-Loaded miRNA in Osteosarcoma.

Authors:  Peng Yao; Yubao Lu; Zongyan Cai; Tianci Yu; Yuchen Kang; Yu Zhang; Xulong Wang
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 3.302

Review 8.  Advances in the Biological Functions and Mechanisms of miRNAs in the Development of Osteosarcoma.

Authors:  Zihe Dong; Zhipeng Liao; Yonglin He; Chengye Wu; Zixiang Meng; Baolong Qin; Ge Xu; Zeyang Li; Tianxin Sun; Yuyan Wen; Guangjie Li
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

9.  Bioinformatics integrated analysis to investigate candidate biomarkers and associated metabolites in osteosarcoma.

Authors:  Jun Wang; Mingzhi Gong; Zhenggang Xiong; Yangyang Zhao; Deguo Xing
Journal:  J Orthop Surg Res       Date:  2021-07-05       Impact factor: 2.359

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.